Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella

Immix Biopharma, Inc.

On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.
Issued 989,876 shares of common stock to former Nexcella stockholders (including third-party cash investors).
Issued 275,759 restricted stock awards and options to purchase 595,676 shares at $2.47 per share to former Nexcella equity plan participants.
Nexcella stockholders have appraisal rights under Delaware law if they perfect them.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.